The chondrosarcoma market is entering a pivotal phase as the first wave of targeted therapies moves through late-stage development. According to DelveInsight’s analysis, the chondrosarcoma market was valued at approximately USD 15 million across the seven major markets (7MM) — the US, EU4 (Germany, France, Italy, Spain), the UK, and Japan — in 2025. With a projected chondrosarcoma growth rate of 16% CAGR between 2026 and 2036, the space is expected to see meaningful expansion as new mechanisms of action reach patients.
Chondrosarcoma Market Detail
Chondrosarcoma is a cartilage-forming bone cancer and the second most common primary solid tumor of bone after osteogenic sarcoma. It is graded from I to IV, with Grade II accounting for the majority of diagnosed cases. Within the chondrosarcoma market, the US chondrosarcoma market represents the largest single-country opportunity, accounting for roughly USD 10 million of the 2025 total — a reflection of higher diagnostic capacity, greater awareness, and faster adoption of emerging therapeutics compared to other regions in the 7MM.
A defining feature of this market is the complete absence of an approved systemic drug. Surgery remains the only curative option, since chondrosarcoma is notoriously resistant to conventional radiotherapy and chemotherapy. This treatment gap is precisely why the metastatic conventional chondrosarcoma market is drawing increasing attention from biopharma investors and strategists — any therapy demonstrating even modest efficacy could rapidly capture significant share in an underserved population.
Chondrosarcoma Epidemiology, Incidence, and Prevalence
Understanding chondrosarcoma epidemiology is central to sizing the opportunity. DelveInsight estimates that total incident cases of chondrosarcoma across the 7MM reached approximately 2,300 in 2025. Chondrosarcoma incidence is highest among adults in their fourth to sixth decades of life, most frequently arising in the pelvis, femur, humerus, and ribs. Conventional chondrosarcoma makes up around 80% of all diagnosed cases, making it the dominant subtype driving overall chondrosarcoma prevalence figures.
IDH mutations are detected in 50–70% of chondrosarcomas globally, with Japan reporting a mutation rate near 50%. This genetic signature has become the single most important biomarker shaping current drug development, since nearly 65% of cases carry an IDH mutation — a large, identifiable subgroup for precision medicine approaches. Because chondrosarcoma is rare, chondrosarcoma survival rate data — particularly for metastatic and dedifferentiated subtypes — remains poor, reinforcing the urgency behind pipeline innovation.
Drug Pipeline and Companies Shaping the Market
Two companies currently anchor the competitive landscape. Servier is advancing ivosidenib, an oral IDH1 inhibitor, in the Phase III CHONQUER trial for IDH1-mutant conventional chondrosarcoma — one of the most closely watched chondrosarcoma clinical trials underway today. The ivosidenib clinical trial compares the drug against placebo in patients who are untreated or have received one prior systemic regimen, and it has already been incorporated into NCCN guideline recommendations for IDH1-mutant disease.
Inhibrx, meanwhile, is developing INBRX-109 (ozekibart), a tetravalent DR5 agonist antibody delivered intravenously. Positive Phase II data announced in October 2025 support a planned BLA filing, positioning ozekibart as a potential first mover independent of mutation status. Together, these two companies — Servier and Inhibrx — represent the core of near-term innovation, though the broader chondrosarcoma drug class also includes older cytotoxic regimens such as doxorubicin, cisplatin, ifosfamide, gemcitabine, and pazopanib, most of which are extrapolated from osteosarcoma market and Ewing sarcoma protocols rather than validated specifically for chondrosarcoma.
For context, the US osteosarcoma market is considerably larger and more mature, given osteosarcoma’s higher incidence and longer history of chemotherapy-responsive treatment — a useful benchmark when evaluating how a future approved chondrosarcoma therapy might be priced and adopted. Similarly, trends observed in the liposarcoma treatment market, another rare soft-tissue sarcoma space with growing targeted-therapy interest, offer useful parallels for uptake modeling in ultra-orphan bone and soft tissue cancers.
Chondrosarcoma Treatment Guidelines and Unmet Needs
Current chondrosarcoma treatment guidelines emphasize wide surgical resection as the definitive intervention across grades, with chemotherapy reserved for dedifferentiated subtypes where a survival benefit has been demonstrated. Radiation resistance, lack of standardized systemic therapy, and diagnostic delays remain the most pressing unmet needs. Patients and physicians searching for chondrosarcoma clinical trials near me often find limited enrollment options, underscoring the rarity of the disease and the concentration of trial sites at specialized sarcoma centers such as the University of Washington and University College London Hospital.
Outlook
With ivosidenib and ozekibart advancing through late-stage development, the chondrosarcoma market is positioned for a fundamental shift from a surgery-only paradigm to one incorporating genomically and biologically targeted systemic therapy — a transition that mirrors past inflection points in other rare oncology markets.
Latest Reports Offered by Delveinsight
congenital hyperinsulinism market | corneal ulcer market | cyclin-dependent kinase-like 5 deficiency disorder | diabetic gastroparesis market | diabetic ketoacidosis market | diabetic peripheral neuropathy market | diagnostic imaging equipment market | dyslipidemia market | dystrophic epidermolysis bullosa market | eosinophilia market | eosinophilic gastroenteritis market | esophageal cancer market | exophthalmos market | facioscapulohumeral muscular dystrophy market | familial adenomatous polyposis market | fatty acid oxidation disorders market | female infertility market | fertility monitoring devices market | fgfr market | gastroesophageal reflux disease market | genital herpes market | geographic atrophy market |
About Delveinsight
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Kanishk